Scarica l'app Stockscreener
8.91
5.61%
-0.53
Dopo l'orario di chiusura:
8.95
0.04
+0.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$9.44
Aprire:
$9.3
Volume 24 ore:
13.43M
Relative Volume:
0.94
Capitalizzazione di mercato:
$9.33B
Reddito:
$140.98M
Utile/perdita netta:
$-854.60M
Rapporto P/E:
-10.43
EPS:
-0.854
Flusso di cassa netto:
$-299.31M
1 W Prestazione:
+1.60%
1M Prestazione:
+28.76%
6M Prestazione:
+316.36%
1 anno Prestazione:
+227.57%
Intervallo 1D:
$8.63
$9.53
Intervallo di 1 settimana:
$8.51
$9.60
Portata 52W:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.91 | 9.17B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.10 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.93 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunitybio Inc Borsa (IBRX) Ultime notizie
Form 144 IMMUNITYBIO For: 1 July By Investing.com - Investing.com Canada
Form 4 Immunitybio Inc For: 1 July By Investing.com - Investing.com Canada
ImmunityBio director Selecky sells $871k in stock - Investing.com
ImmunityBio director Selecky sells $871k in stock By Investing.com - Investing.com Canada
ImmunityBio (IBRX) director pre-plans option exercises and sells 96,722 shares - Stock Titan
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
IBRX (NASDAQ) insider exercise 1,000 shares; 95,722-share 10b5-1 sale - Stock Titan
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes - Stocktwits
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales - Stocktwits
[144] ImmunityBio, Inc. SEC Filing - Stock Titan
ImmunityBio, Inc.(NasdaqGS: IBRX) dropped from Russell 2000 Value Benchmark - marketscreener.com
IBRX Stock Is Back: Anktiva Now Targets Severe Pneumonia After Clearing Key Checkpoint In Bladder Cancer Trial - Stocktwits
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last? - Yahoo Finance
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
Enterprise value to revenue forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology - Stocktwits
IBRX Stock Lights Up: Retail Cheers Calls For Trump To ‘Pull The Plug’ On FDA Chief Marty Makary Amid Anktiva Row - Stocktwits
Enterprise value to revenue forward of ImmunityBio Inc – TRADEGATE:26CA - TradingView
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
ImmunityBio, Inc.(NasdaqGS: IBRX) dropped from Russell 3000E Value Benchmark - marketscreener.com
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
2026-06-28 | ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:IBRX | Press Release - Stockhouse
IBRX Stock Enters Heavy Catalyst Phase: Traders Brace For Key Anktiva Decision Amid Trump’s FDA Turmoil - Stocktwits
IBRX Stock Jumps After-Hours: Bulls Cheer ‘Unstoppable’ Global Expansion Amid US Regulatory Heat For Anktiva - Stocktwits
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews - Stocktwits
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally - Stocktwits
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume - TechStock²
Enterprise value to EBITDA forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
Form 4 Immunitybio Inc For: 26 June By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to EBIT forward of ImmunityBio Inc – SWB:26CA - TradingView
Director Barry Simon Sells 25,000 Shares of ImmunityBio Inc (IBR - GuruFocus
ImmunityBio (NASDAQ: IBRX) director sells 25,000 shares under 10b5-1 plan - Stock Titan
ImmunityBio director Simon Barry J. sells $196,907 of common stock - Investing.com
ImmunityBio director Simon Barry J. sells $196,907 of common stock By Investing.com - Investing.com Nigeria
Price to sales forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
ImmunityBio (NASDAQ:IBRX) rises as Russell index rebalancing and high multiple draw buyers - TechStock²
Price to earnings forward of ImmunityBio Inc – SWB:26CA - TradingView
IBRX Stock Climbs As ANKTIVA Data Spotlight Draws Traders - StocksToTrade
ImmunityBio Confirms Trial Strength For Anktiva In Bladder Cancer - Stocktwits
Price to sales forward of ImmunityBio Inc – SWB:26CA - TradingView
IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds - Stocktwits
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
ImmunityBio reports progress on bladder cancer filing, shares trade quietly on NASDAQ - Ad-hoc-news.de
Immunitybio Inc (IBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunitybio Inc Azioni (IBRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Selecky Christobel | Director |
Jun 29 '26 |
Option Exercise |
2.94 |
95,722 |
281,387 |
95,722 |
| Selecky Christobel | Director |
Jun 30 '26 |
Option Exercise |
2.98 |
1,000 |
2,983 |
1,000 |
| Selecky Christobel | Director |
Jun 29 '26 |
Sale |
9.01 |
95,722 |
862,216 |
0 |
| Selecky Christobel | Director |
Jun 30 '26 |
Sale |
9.00 |
1,000 |
9,000 |
0 |
0.05%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):